Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2000/04/01
-
Indian UGC (journal)
-
Refrences45
-
Citations62
-
Akhondzadeh
-
Shasavand
-
Jamilian
-
Shabestari
-
Kamalipour
Journal Categories
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
You May Also Like
- A Bayesian neural network method for adverse drug reaction signal generation
- Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- Clinical consequences of polypharmacy in elderly
- Long-term side effects of glucocorticoids
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia | Journal of Clinical Pharmacy and Therapeutics |
| 46 | 1999 |
| Adenosine and the Nervous System: Clinical Implications | Clinical Neuropharmacology |
| 27 | 1996 |
| Perspektiven zur Therapie neuropsychiatrischer Erkrankungen mit adenosinergen Substanzen | Fortschritte der Neurologie · Psychiatrie |
| 10 | 1995 |
Recent advances in the pharmacotherapy of schxzophrenia | Acta Psychiatrica Scandinavica |
| 33 | 1994 |
| 10.1007/BF01880657 | 1994 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Molecular and Structural Insight into Adenosine A2A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach | Molecular Neurobiology |
| 1 | 2023 |
| Novel pharmacotherapy targeting the positive symptoms of schizophrenia | Expert Opinion on Pharmacotherapy |
| 1 | 2023 |
The adenosine hypothesis of schizophrenia into its third decade: From neurochemical imbalance to early life etiological risks | Frontiers in Cellular Neuroscience |
| 3 | 2023 |
| Unfolding the Potency of Adenosine in Targeting Triple Negative Breast Cancer via Paclitaxel-Incorporated pH-Responsive Stealth Liposomes | ACS Biomaterials Science & Engineering |
| 13 | 2022 |
Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer a Pathway to Treatment? | International Journal of Molecular Sciences |
| 3 | 2022 |
Citations Analysis
The category
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry 39
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Allopurinol augmentation for poorly responsive schizophrenia and was published in 2001. The most recent citation comes from a 2023 study titled Novel pharmacotherapy targeting the positive symptoms of schizophrenia. This article reached its peak citation in 2012, with 6 citations. It has been cited in 44 different journals, 15% of which are open access. Among related journals, the Neuropharmacology cited this research the most, with 5 citations. The chart below illustrates the annual citation trends for this article.